Research programme: mitochondrial disorders therapeutics - Vincere Biosciences
Latest Information Update: 25 Aug 2023
At a glance
- Originator Vincere Biosciences
- Class Small molecules
- Mechanism of Action Mitochondrial protein modulators; Parkin protein modulators; Usp30 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mitochondrial disorders
Most Recent Events
- 27 Jul 2023 Research programme: mitochondrial disorders therapeutics - Vincere Biosciences is available for licensing as of 27 Jul 2023. https://www.vincerebio.com/
- 27 Jul 2023 Early research in Mitochondrial disorders in USA (unspecified route) (Vincere Biosciences website, July 2023)